Información de NuCana PLC, dividendo de NuCana PLC, actividades de los accionistas y más

Información de NuCana PLC Compañía

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Información de la empresa

Código de la empresaNCNA

Nombre de la empresaNuCana PLC

Fecha de salida a bolsaSep 28, 2017

Fundada en1997

Director ejecutivoMr. Hugh S. Griffith

Número de empleados20

Tipo de títulosDepository Receipt

Fin del año fiscalSep 28

DirecciónLochside House

CiudadEDINBURGH

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited Kingdom

Código postalEH12 9DT

Teléfono4401313571111

Sitio Webhttps://www.nucana.com/

Código de la empresaNCNA

Fecha de salida a bolsaSep 28, 2017

Fundada en1997

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Mr. Hugh S. Griffith

Chief Executive Officer, Co-Founder, Executive Director

10.60K

--

Mr. Martin Mellish

Non-Executive Independent Director

1.33K

+18.87%

Dr. Elliott M. Levy, M.D.

Non-Executive Independent Director

749.00

+298.40%

Dr. Bali Muralidhar, M.D., Ph.D

Non-Executive Independent Director

22.00

--

Dr. Jeffrey D. Bloss, M.D.

Chief Medical Officer

--

Mr. Andrew Kay

Non-Executive Independent Chairman of the Board

--

Dr. Cyrille Leperlier, M.D.

Non-Executive Independent Director

--

Mr. Christopher F. Brinzey

Investor Relations

--

Dr. David Harrison, M.D.

Head - Translational Studies

--

Mr. Donald (Don) Munoz

Chief Financial Officer

--

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Mr. Hugh S. Griffith

Chief Executive Officer, Co-Founder, Executive Director

10.60K

--

Mr. Martin Mellish

Non-Executive Independent Director

1.33K

+18.87%

Dr. Elliott M. Levy, M.D.

Non-Executive Independent Director

749.00

+298.40%

Dr. Bali Muralidhar, M.D., Ph.D

Non-Executive Independent Director

22.00

--

Dr. Jeffrey D. Bloss, M.D.

Chief Medical Officer

--

Mr. Andrew Kay

Non-Executive Independent Chairman of the Board

--

Desglose de ingresos

No datos encontrados

No datos encontrados

Por negocio

Por región

No datos encontrados

Accionista

Hora de actualización: sáb., 22 de mar

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

Sofinnova Investments, Inc

3.51%

Abingworth Management Limited

2.35%

Susquehanna International Group, LLP

0.82%

Schonfeld Strategic Advisors LLC

0.79%

Acadian Asset Management LLC

0.75%

Other

91.78%

Estadísticas de accionistas

Accionista

Proporción

Sofinnova Investments, Inc

3.51%

Abingworth Management Limited

2.35%

Susquehanna International Group, LLP

0.82%

Schonfeld Strategic Advisors LLC

0.79%

Acadian Asset Management LLC

0.75%

Other

91.78%

Tipo

Accionista

Proporción

Venture Capital

5.86%

Investment Advisor

2.08%

Hedge Fund

1.60%

Research Firm

1.12%

Investment Advisor/Hedge Fund

0.78%

Individual Investor

0.22%

Other

88.33%

Participación institucional

Hora de actualización: mar., 4 de mar

Periodo de informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

50

678.81K

11.95%

+387.28K

2024Q4

52

469.91K

11.91%

+42.72K

2024Q3

52

279.81K

7.09%

-247.00K

2024Q2

51

362.89K

15.79%

-1.48K

2024Q1

59

340.51K

14.80%

-343.96K

2023Q4

65

549.25K

25.71%

-320.80K

2023Q3

68

668.24K

31.65%

-112.66K

2023Q2

71

571.34K

27.26%

-362.30K

2023Q1

81

667.89K

31.87%

-504.63K

2022Q4

87

672.60K

32.11%

-559.71K

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Sofinnova Investments, Inc

199.52K

3.51%

+199.52K

--

Feb 14, 2025

Abingworth Management Limited

133.33K

2.35%

--

Dec 31, 2024

Susquehanna International Group, LLP

46.72K

0.82%

+46.72K

--

Dec 31, 2024

Schonfeld Strategic Advisors LLC

45.07K

0.79%

+45.07K

--

Dec 31, 2024

Acadian Asset Management LLC

42.41K

0.75%

+18.79K

+79.54%

Dec 31, 2024

Virtu Americas LLC

40.40K

0.71%

+40.40K

--

Dec 31, 2024

Baillie Gifford & Co.

36.70K

0.65%

--

Dec 31, 2024

Citadel Advisors LLC

25.00K

0.44%

+25.00K

--

Dec 31, 2024

Two Sigma Investments, LP

20.99K

0.37%

+20.99K

--

Dec 31, 2024

Glass Jacobson Wealth Advisors

15.00K

0.26%

--

Dec 31, 2024

ETF relacionados

Nombre

Proporción

No datos encontrados

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

No datos encontrados

División de acciones

Fecha

Tipo

Relación

Apr 12, 2024

Merger

25<1

Apr 12, 2024

Merger

25<1

Apr 12, 2024

Merger

25<1

Apr 12, 2024

Merger

25<1

Fecha

Tipo

Relación

Apr 12, 2024

Merger

25<1

Apr 12, 2024

Merger

25<1

Apr 12, 2024

Merger

25<1

Apr 12, 2024

Merger

25<1

NuCana PLC

0.660USD

NuCana PLC

0.660

Descripción general

Compañía